Opportunities to Optimize Cancer Policies Panel Discussion

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Welcome and Introduction to Vi3C

FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma

Hypofractionated Locoregional RT in Early Breast Cancer

Melanoma-Specific Survival With Sentinel Lymph Node Biopsy

Breast Cancer Ultrasensitive ctDNA Assay Findings and Outcomes After Neoadjuvant Therapy

AMA Survey Finds Rapid Growth in Physician AI Adoption